ACR management guidelines for the treatment of gout: What’s new and what’s controversial
https://doi.org/10.47360/1995-4484-2021-129-133
Abstract
The community of many national and international recommendations dedicated to the treatment of a specific disease, including gout, is fully justified, since it allows taking into account, for example, regional, ethnic characteristics of the manifestations of the disease, which can be important when choosing a therapy. However, this is often associated with dissonance regarding the solution of key issues facing the practitioner. The publication in 2020 of the updated American College of Rheumatology (ACR) guidelines for the management of gout revealed controversy with some of the previous version’s postulates, as well as with other similar work, for example, with the guidelines published in the same year and the French Association of Rheumatology. Among the controversial provisions of the new version of the ACR recommendations are the unified target level of uric acid for all patients, indications for drug therapy, the choice of a drug in patients with reduced renal function, prevention of arthritis attacks when starting uratelowering therapy. This article discusses these and other controversial issues in gout therapy based on an analysis of the latest ACR guidelines.
About the Author
M. S. Eliseev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Maksim S. Eliseev
115522, Moscow, Kashirskoye Highway, 34A
References
1. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken). 2020;72(6):744-760. doi: 10.1002/acr.24180
2. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res. 2012;64(10):1431-1446. doi: 10.1002/acr.21772
3. Khanna D, Khanna PP, Fitzgerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res. 2012;64(10):1447-1461. doi: 10.1002/acr.21773
4. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707
5. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016. Arthritis Rheum. 2019;71(6):991-999. doi: 10.1002/art.40807
6. Juraschek SP, Kovell LC, Miller ER, Gelber AC. Gout, urate-lowering therapy, and uric acid levels among adults in the United States. Arthritis Care Res (Hoboken). 2015;67(4):588-592. doi: 10.1002/acr.22469
7. Taylor W, Dalbeth N, Saag KG, Singh JA, Rahn EJ, Mudano AS, et al. Flare rate thresholds for patient assessment of disease activity states in gout. J Rheumatol. 2021;48(2):293-298. doi: 10.3899/jrheum.191242
8. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123. doi: 10.1186/s12916-017-0890-9
9. Perez-Ruiz F, Martinez-Indart L, Carmona L, HerreroBeites AM, Pijoan JI, Krishnan E. Tophaceous gout and high level of hyperuricaemia are both associated with increased risk of mortality in patients with gout. Ann Rheum Dis. 2014;73:177-182. doi: 10.1136/annrheumdis-2012-202421
10. Eliseev MS. Chronic kidney disease: The role of hyperuricemia and the possibility of urate-lowering therapy. Sovremennaya revmatologia = Modern Rheumatology Journal. 2018;12(1):60-65 (In Russ.). doi: 10.14412/1996-70122018-1-60-65
11. Pagidipati NJ, Clare RM, Keenan RT, Chiswell K, Roe MT, Hess CN. Association of gout with long-term cardiovascular outcomes among patients with obstructive coronary artery disease. J Am Heart Assoc. 2018;7:e009328. doi: 10.1161/JAHA.118.009328
12. Pérez Ruiz F, Richette P, Stack AG, Karra Gurunath R, García de Yébenes MJ, Carmona L. Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality. RMD Open. 2019;5(2):e001015. doi: 10.1136/rmdopen-2019-001015
13. Pascart T, Latourte A, Flipo RM, Chalès G, CoblentzBaumann L, Cohen-Solal A, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020;87(5):395-404. doi: 10.1016/j.jbspin.2020.05.002
14. Dalbeth N, Billington K, Doyle A, Frampton C, Tan P, Aati O, et al. Effects of allopurinol dose escalation on bone erosion and urate volume in gout: A dual-energy computed tomography imaging study within a randomized, controlled trial. Arthritis Rheumatol. 2019;71:1739-1746. doi: 10.1002/art.40929
15. Ellmann H, Bayat S, Araujo E, Manger B, Kleyer A, Cavallaro A, et al. Effects of conventional uric acid-lowering therapy on monosodium urate crystal deposits. Arthritis Rheumatol. 2020;72(1):150-156. doi: 10.1002/art.41063
16. Doherty M, Jenkins W, Richardson H, Sarmanova A, Abhishek A, Ashton D, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomized controlled trial. Lancet. 2018;392:1403-1412. doi: 10.1016/S01406736(18)32158-5
17. White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378(13):1200-1210. doi: 10.1056/NEJMoa1710895
18. Eliseev MS. Cardiovascular safety of febuxostat. Analysis of the CARES study. Sovremennaya revmatologia = Modern Rheumatology Journal. 2018;12(4):42-46 (In Russ.). doi: 10/14412/1996-7012-2018-4-42-46
19. U.S. Food and Drug Administartion. Safety alerts for human medical products. URL: https://www.fda.gov/drugs/drugsafety/ucm584702.htm
20. Juge PA, Truchetet ME, Pillebout E, Ottaviani S, Vigneau C, Loustau C, et al. Efficacy and safety of febuxostat in 73 gouty patients with stage 4/5 chronic kidney disease: A retrospective study of 10 centers. Joint Bone Spine. 2017;84(5):595-598. doi: 10.1016/j.jbspin.2016.09.020
21. Kim SH, Lee SY, Kim JM, Son CN. Renal safety and urate-lowering efficacy of febuxostat in gout patients with stage 4-5 chronic kidney disease not yet on dialysis. Korean J Intern Med. 2020;35(4):998-1003. doi: 10.3904/kjim.2018.423
22. Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, et al. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): A multicentre, prospective, randomised, open-label, non-inferiority trial. Lancet. 2020;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0
23. Boger WP, Strickland SC. PROBENECID (BENEMID): Its uses and side-effects in 2,502 patients. AMA Arch Intern Med. 1955;95:83-92. doi: 10.1001/archinte.1955.00250070099012
24. Lipsky PE, Edwards NL, Fields TR, Keenan RT, Mandell BF, Schlesinger N. Response to the 2020 American College of Rheumatology Guideline for the management of gout: Comment on the article by FitzGerald et al. Arthritis Care Res (Hoboken). 2020;72(10):1506-1507. doi: 10.1002/acr.24379
25. Yamanaka H, Tamaki S, Ide Y, Kim H, Inoue K, Sugimoto M, et al. Stepwise dose increase of febuxostat is comparable with colchicine prophylaxis for the prevention of gout flares during the initial phase of urate-lowering therapy: Results from FORTUNE-1, a prospective, multicentre randomised study. Ann Rheum Dis. 2018;77(2):270-276. doi: 10.1136/annrheumdis-2017-211574
26. Chikina MN, Ilyinykh EV, Eliseev MS. Adherence to urate-lowering therapy while following the national guidelines for the management of patients with gout (preliminary evidence). Sovremennaya revmatologia = Modern Rheumatology Journal. 2020;14(4):70-75 (In Russ.) doi: 10.14412/1996-70122020-4-70-75
27. Chikina MN, Eliseev MS, Zhelyabina OV. Practical application of national clinical guidelines for the management of gout (preliminary data). Sovremennaya revmatologia = Modern Rheumatology Journal. 2020;14(2):97-103 (In Russ.). doi: 10.14412/1996-7012-2020-2-97-103.
28. Yu J, Qiu Q, Liang L, Yang X, Xu H. Prophylaxis of acute flares when initiating febuxostat for chronic gouty arthritis in a real-world clinical setting. Mod Rheumatol. 2018;28(2):339-344. doi: 10.1080/14397595.2017.1318467
29. Chikina MN, Elisеev MS. Comparison of efficacy and safety of different anti-inflammatory drugs at initiation of urate-lowering therapy in patients with gout (preliminary data). Ann Rheum Dis. 2020;79(1):1757. doi: 10.1136/annrheumdis-2020-eular.5164
30. Association of Rheumatologists of Russia. Gout. Clinical guidelines .2018 (In Russ.). URL: http://cr.rosminzdrav.ru/recomend/251_1 (Дата доступа: 01.02.2021)
31. Solomon DH, Glynn RJ, MacFadyen JG, Libby P, Thuren T, Everett BM, et al. Relationship of interleukin-1β blockade with incident gout and serum uric acid levels: exploratory analysis of a randomized controlled trial. Ann Intern Med. 2018;169(8):535-542. doi: 10.7326/M18-1167
32. Eliseev MS, Zhelyabina OV, Mukagova MV, Nasonov EL. Clinical experience with the interleukin-1β blocker canakinumab in patients with chronic tophaceous gout: abolishment of arthritis and prevention of exacerbations when allopurinol is used. Sovremennaya revmatologia = Modern Rheumatology Journal. 2015;9(2):16-22 (In Russ.). doi: 10.14412/1996-7012-2015-2-16-22
33. Flynn TJ, Cadzow M, Dalbeth N, Jones PB, Stamp LK, Hindmarsh JH, et al. Positive association of tomato consumption with serum urate: support for tomato consumption as an anecdotal trigger of gout flares. BMC Musculoskelet Disord. 2015;16:196. doi: 10.1186/s12891-015-0661-8
34. Zhang Y, Chen C, Choi H, Chaisson C, Hunter D, Niu J, et al. Purine-rich foods intake and recurrent gout attacks. Ann Rheum Dis. 2012;71(9):1448-1453. doi: 10.1136/annrheumdis-2011-201215
35. Nguyen UD, Zhang Y, Louie-Gao Q, Niu J, Felson DT, LaValley MP, et al. Obesity paradox in recurrent attacks of gout in observational studies: Clarification and remedy. Arthritis Care Res (Hoboken). 2017;69(4):561-566. doi: 10.1002/acr.22954
36. Romero-Talamás H, Daigle CR, Aminian A, Corcelles R, Brethauer SA, Schauer PR. The effect of bariatric surgery on gout: A comparative study. Surg Obes Relat Dis. 2014;10(6):1161-1165. doi: 10.1016/j.soard.2014.02.025
37. Juraschek SP, Miller ER III, Gelber AC. Effect of oral vitamin C supplementation on serum uric acid: a meta-analysis of randomized controlled trials. Arthritis Care Res (Hoboken). 2011;63:12951306. doi: 10.1002/acr.20519
Review
For citations:
Eliseev M.S. ACR management guidelines for the treatment of gout: What’s new and what’s controversial. Rheumatology Science and Practice. 2021;59(2):129-133. (In Russ.) https://doi.org/10.47360/1995-4484-2021-129-133
Views:
5895
Email this article 